Novo­cure to lay off 200 work­ers, nar­row pipeline for elec­tric fields can­cer ther­a­py

Novo­cure said it will lay off 13% of its glob­al work­force, or about 200 em­ploy­ees, as part of a $60 mil­lion cull in its op­er­at­ing spend­ing.

The Swiss on­col­o­gy drug­mak­er said Tues­day it will now fo­cus its de­vel­op­ment work on a trio of ran­dom­ized tri­als — TRI­DENT, KEYNOTE D58 and LU­NAR-2 — for its so-called Tu­mor Treat­ing Fields ther­a­py.

The biotech al­so ex­pects Phase III read­outs next year for two ran­dom­ized stud­ies in brain metas­tases from non-small cell lung can­cer and lo­cal­ly ad­vanced pan­cre­at­ic can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER